image
Healthcare - Drug Manufacturers - General - NASDAQ - UK
$ 70.07
-2.54 %
$ 434 B
Market Cap
28.33
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 8, 2025.

The intrinsic value of one AZN stock under the worst case scenario is HIDDEN Compared to the current market price of 70.1 USD, AstraZeneca PLC is HIDDEN

This DCF valuation model was last updated on May, 8, 2025.

The intrinsic value of one AZN stock under the base case scenario is HIDDEN Compared to the current market price of 70.1 USD, AstraZeneca PLC is HIDDEN

This DCF valuation model was last updated on May, 8, 2025.

The intrinsic value of one AZN stock under the best case scenario is HIDDEN Compared to the current market price of 70.1 USD, AstraZeneca PLC is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AZN

image
$78.0$78.0$76.0$76.0$74.0$74.0$72.0$72.0$70.0$70.0$68.0$68.0$66.0$66.0$64.0$64.0$62.0$62.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
54.1 B REVENUE
18.03%
10 B OPERATING INCOME
22.09%
8.69 B NET INCOME
25.97%
11.9 B OPERATING CASH FLOW
14.65%
-7.98 B INVESTING CASH FLOW
-96.36%
-4 B FINANCING CASH FLOW
39.15%
13.6 B REVENUE
-8.75%
3.67 B OPERATING INCOME
80.45%
3.4 B NET INCOME
104.20%
3.71 B OPERATING CASH FLOW
27.73%
-1.25 B INVESTING CASH FLOW
-6.10%
-2.71 B FINANCING CASH FLOW
-303.43%
Balance Sheet AstraZeneca PLC
image
Current Assets 25.8 B
Cash & Short-Term Investments 5.65 B
Receivables 11.2 B
Other Current Assets 8.94 B
Non-Current Assets 78.2 B
Long-Term Investments 1.73 B
PP&E 11.6 B
Other Non-Current Assets 64.8 B
5.43 %10.80 %8.59 %11.20 %62.31 %Total Assets$104.0b
Current Liabilities 27.9 B
Accounts Payable 3.64 B
Short-Term Debt 2.5 B
Other Current Liabilities 21.7 B
Non-Current Liabilities 35.3 B
Long-Term Debt 27.6 B
Other Non-Current Liabilities 7.68 B
5.76 %3.95 %34.40 %43.73 %12.16 %Total Liabilities$63.2b
EFFICIENCY
Earnings Waterfall AstraZeneca PLC
image
Revenue 54.1 B
Cost Of Revenue 10.2 B
Gross Profit 43.9 B
Operating Expenses 33.9 B
Operating Income 10 B
Other Expenses 1.31 B
Net Income 8.69 B
60b60b50b50b40b40b30b30b20b20b10b10b0054b(10b)44b(34b)10b(1b)9bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
81.12% GROSS MARGIN
81.12%
18.50% OPERATING MARGIN
18.50%
13.01% NET MARGIN
13.01%
17.25% ROE
17.25%
6.76% ROA
6.76%
10.30% ROIC
10.30%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis AstraZeneca PLC
image
8b8b7b7b6b6b5b5b4b4b3b3b2b2b1b1b0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 8.69 B
Depreciation & Amortization 6.69 B
Capital Expenditures -4.59 B
Stock-Based Compensation 0
Change in Working Capital -893 M
Others -3.52 B
Free Cash Flow 7.28 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets AstraZeneca PLC
image
Wall Street analysts predict an average 1-year price target for AZN of $86 , with forecasts ranging from a low of $82 to a high of $89 .
AZN Lowest Price Target Wall Street Target
82 USD 17.03%
AZN Average Price Target Wall Street Target
86 USD 22.73%
AZN Highest Price Target Wall Street Target
89 USD 27.02%
Price
Max Price Target
Min Price Target
Average Price Target
9090858580807575707065656060Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
1.49% DIVIDEND YIELD
1.05 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
1.6001.6001.4001.4001.2001.2001.0001.0000.8000.8000.6000.6000.4000.4000.2000.2000.0000.0000.950.950.950.950.950.950.950.9850.9850.9851.050.451.400.451.400.451.400.451.400.451.400.451.400.451.400.4651.450.4651.450.491.481.052015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership AstraZeneca PLC
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
AstraZeneca and GSK slide as Trump and RFK appoint new FDA vaccine chief Shares in AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) on the back of an appointment by Donald Trump and his health secretary Robert F Kennedy Jnr of a key position at the US drug regulator.  Vinay Prasad, a vaccine sceptic like Kennedy, has been made head of the US Food and Drug Administration's Center for Biologics Evaluation and Research. proactiveinvestors.co.uk - 1 week ago
AZN or ARGX: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Astrazeneca (AZN) or argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now? zacks.com - 2 weeks ago
AstraZeneca's Breztri meets main goals of late-stage asthma trials Anglo-Swedish drugmaker AstraZeneca on Friday said its inhaler therapy Breztri Aerosphere met all the main goals of two late-stage trials in patients with uncontrolled asthma. reuters.com - 2 weeks ago
AstraZeneca has plenty coming down the pipeline to appease the bears AstraZeneca PLC (LSE:AZN) investors looking beyond the short-term noise of Medicare reform and currency headwinds may want to focus on a growing pipeline of clinical catalysts and a valuation that UBS believes underplays the company's longer-term potential. The bank retains its 'buy' rating with a price target of 14,200p, offering more than 30% upside from the current share price of around 10,600p. proactiveinvestors.co.uk - 2 weeks ago
AstraZeneca has built resilient supply chains in U.S., China: CEO AstraZeneca CEO Pascal Soriot discusses earnings, the potential trade tariff impact on the business and the outlook for the firm's key markets. youtube.com - 3 weeks ago
Pharma firms maastraz Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector. youtube.com - 3 weeks ago
AstraZeneca PLC (AZN) Q1 2025 Earnings Conference Call Transcript AstraZeneca PLC (NASDAQ:AZN ) Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ET Company Participants Andy Barnett - Head of IR Pascal Soriot - Executive Director and CEO Aradhana Sarin - Executive Director and CFO Dave Fredrickson - EVP, Oncology Business Unit Susan Galbraith - EVP, Oncology R&D Ruud Dobber - EVP, BioPharmaceuticals Business Unit Sharon Barr - EVP, BioPharmaceuticals R&D Marc Dunoyer - CEO, Alexion Iskra Reic - EVP, International Conference Call Participants Sarita Kapila - Morgan Stanley James Gordon - JPMorgan Rajan Sharma - Goldman Sachs? Sachin Jain - Bank of America Steve Scala - Cowen Mattias Haggblom - Handelsbanken Matthew Weston - UBS Justin Smith - Bernstein Seamus Fernandez - Guggenheim Simon Baker - Redburn Rajesh Kumar - HSBC Luisa Hector - Berenberg Peter Verdult - BNP Operator Good morning to those joining from the UK and the U.S. Good afternoon to those in Central Europe and good evening to those listening in Asia. seekingalpha.com - 3 weeks ago
AstraZeneca CEO talks tariffs, first quarter earnings AstraZeneca (AZN) reported mixed first quarter earnings results, missing on revenue estimates but beating on earnings per share (EPS). The company also reaffirmed its 2025 outlook and has highlighted its commitment to US investments amid tariff concerns. youtube.com - 3 weeks ago
AstraZeneca shares claw their way back into green after revenue miss After an early stumble, AstraZeneca PLC (LSE:AZN) shares pulled back to level by the close on Tuesday, but analysts see reasons for investors to stay watchful despite the apparent strength of the results. At face value, the update looked reassuring. proactiveinvestors.co.uk - 3 weeks ago
Here's Why Astrazeneca (AZN) is a Strong Value Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 3 weeks ago
Astrazeneca (AZN) Reports Q1 Earnings: What Key Metrics Have to Say The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 3 weeks ago
AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key Drugs AstraZeneca reports mixed first-quarter 2025 results. The fall in pre-market is likely due to the soft sales performance of key drugs across the oncology and rare disease segments. zacks.com - 3 weeks ago
8. Profile Summary

AstraZeneca PLC AZN

image
COUNTRY UK
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 434 B
Dividend Yield 1.49%
Description AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Contact 1 Francis Crick Avenue, Cambridge, CB2 0AA https://www.astrazeneca.com
IPO Date May 12, 1993
Employees 94300
Officers Mr. Jeffrey Pott J.D. CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board Ms. Iskra Reic Executive Vice President of International Gonzalo Vina Head of Global Media Relations Mr. David Fredrickson Executive Vice-President of Oncology Haematology Business Unit Ms. Pam P. Cheng EVice President of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board Dr. Ruud Dobber Ph.D. Executive Vice-President of BioPharmaceuticals Business Unit Dr. Aradhana Sarin M.D. Chief Financial Officer & Executive Director Dr. Susan Mary Galbraith M.D., Ph.D. Executive Vice President of Oncology Haematology R&D Mr. Andrew P. Barnett Head of Investor Relations Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. Chief Executive Officer & Executive Director